2021 Biotech IPOs Get Off to a Roaring Start
The Pharma Data
JANUARY 19, 2021
With this kind of a start, 2021 may be scorching. The company hopes to raise $140 million of common stock, which will be used to advance its clinical and earlier stage programs and for R&D, working capital and general corporate purposes. TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers.
Let's personalize your content